Allogeneic hematopoietic stem cell transplantation(HSCT)is one of the most effective options for hematological malignancies,and human leukocyte antigen-partially matched related donors(PMRDs)are a valuable option for ...Allogeneic hematopoietic stem cell transplantation(HSCT)is one of the most effective options for hematological malignancies,and human leukocyte antigen-partially matched related donors(PMRDs)are a valuable option for HSCT.Several protocols(with or without ex vivo T-cell depletion(TCD))have been established worldwide.TCD including CD34+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen disparity.However,TCD is associated with prolonged immune deficiencies,increased risks of infectious complications,and high transplantation-related mortality.PMRD HSCT without ex vivo TCD is well developed,and numerous patients have benefitted from it.Here,we review the literature on PMRD HSCT.展开更多
基金This work was partly supported by the National High Technology Research and Development Program of China(863 Program)(Grant No.2011AA020105)the Key Program of National Natural Science Foundation of China(Grant No.81230013).
文摘Allogeneic hematopoietic stem cell transplantation(HSCT)is one of the most effective options for hematological malignancies,and human leukocyte antigen-partially matched related donors(PMRDs)are a valuable option for HSCT.Several protocols(with or without ex vivo T-cell depletion(TCD))have been established worldwide.TCD including CD34+positive selection and CD3/CD19 depletion has successfully overcome the human leukocyte antigen disparity.However,TCD is associated with prolonged immune deficiencies,increased risks of infectious complications,and high transplantation-related mortality.PMRD HSCT without ex vivo TCD is well developed,and numerous patients have benefitted from it.Here,we review the literature on PMRD HSCT.
